Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.

Schuette W, Schirmacher P, Eberhardt WEE, Dietel M, Zirrgiebel U, Muehlenhoff L, Thomas M.

BMC Cancer. 2018 Feb 5;18(1):135. doi: 10.1186/s12885-018-4032-3.

2.

Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.

Hirsch B, Endris V, Lassmann S, Weichert W, Pfarr N, Schirmacher P, Kovaleva V, Werner M, Bonzheim I, Fend F, Sperveslage J, Kaulich K, Zacher A, Reifenberger G, Köhrer K, Stepanow S, Lerke S, Mayr T, Aust DE, Baretton G, Weidner S, Jung A, Kirchner T, Hansmann ML, Burbat L, von der Wall E, Dietel M, Hummel M.

Virchows Arch. 2018 Apr;472(4):557-565. doi: 10.1007/s00428-017-2288-7. Epub 2018 Jan 27.

3.

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.

Braicu EI, Darb-Esfahani S, Schmitt WD, Koistinen KM, Heiskanen L, Pöhö P, Budczies J, Kuhberg M, Dietel M, Frezza C, Denkert C, Sehouli J, Hilvo M.

Oncotarget. 2017 Oct 26;8(61):102912-102922. doi: 10.18632/oncotarget.22076. eCollection 2017 Nov 28.

4.

Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.

Kristiansen I, Stephan C, Jung K, Dietel M, Rieger A, Tolkach Y, Kristiansen G.

Int J Mol Sci. 2017 May 29;18(6). pii: E1151. doi: 10.3390/ijms18061151.

5.

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.

Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A.

Oncoimmunology. 2017 Jan 27;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017.

6.

HER2 testing in gastric cancer: results of a German expert meeting.

Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G.

J Cancer Res Clin Oncol. 2017 May;143(5):835-841. doi: 10.1007/s00432-017-2374-x. Epub 2017 Mar 11. Review.

7.

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.

Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E.

Virchows Arch. 2016 Nov;469(5):489-503. Epub 2016 Aug 17. Review.

8.

Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia.

Von Laffert M, Hänel M, Dietel M, Anagnostopoulos I, Jöhrens K.

Oncol Lett. 2016 Oct;12(4):2421-2428. Epub 2016 Aug 5.

9.

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Denkert C, Stenzinger A, Salat C, Sinn B, Schem C, Endris V, Klare P, Schmitt W, Blohmer JU, Weichert W, Möbs M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Loi S, Untch M, von Minckwitz G, Nekljudova V, Loibl S.

Oncotarget. 2016 Oct 18;7(42):67686-67698. doi: 10.18632/oncotarget.11891.

10.

Classical pathology and mutational load of breast cancer - integration of two worlds.

Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz JK, Györffy B, Dietel M, Loibl S, Weichert W, Stenzinger A.

J Pathol Clin Res. 2015 Jul 20;1(4):225-38. doi: 10.1002/cjp2.25. eCollection 2015 Oct.

11.

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.

Löffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, Folprecht G, Stenzinger A, Dietel M, Weichert W, Krämer A.

Oncotarget. 2016 Jul 12;7(28):44322-44329. doi: 10.18632/oncotarget.10035.

12.

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment.

Budczies J, Pfarr N, Stenzinger A, Treue D, Endris V, Ismaeel F, Bangemann N, Blohmer JU, Dietel M, Loibl S, Klauschen F, Weichert W, Denkert C.

Oncotarget. 2016 Mar 15;7(11):13236-47. doi: 10.18632/oncotarget.7451.

13.

Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer.

Roßner F, Gieseler C, Morkel M, Royer HD, Rivera M, Bläker H, Dietel M, Schäfer R, Sers C.

Oncogenesis. 2016 Jan 18;5:e187. doi: 10.1038/oncsis.2015.51.

14.

Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.

Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI.

Cancer Res. 2016 Feb 15;76(4):796-804. doi: 10.1158/0008-5472.CAN-15-2298. Epub 2015 Dec 18.

15.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K.

Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429.

16.

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.

Arsenic R, Treue D, Lehmann A, Hummel M, Dietel M, Denkert C, Budczies J.

BMC Clin Pathol. 2015 Nov 18;15:20. doi: 10.1186/s12907-015-0020-6. eCollection 2015.

17.

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.

Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, García RC, Kerr KM, Lim E, López-Ríos F, Thunnissen E, Van Schil PE, von Laffert M.

Thorax. 2016 Feb;71(2):177-84. doi: 10.1136/thoraxjnl-2014-206677. Epub 2015 Nov 3. Review.

18.

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.

Arsenic R, Braicu EI, Letsch A, Dietel M, Sehouli J, Keilholz U, Ochsenreither S.

BMC Cancer. 2015 Oct 24;15:784. doi: 10.1186/s12885-015-1824-6.

19.

The combinatorial complexity of cancer precision medicine.

Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A.

Oncoscience. 2014 Jul 23;1(7):504-9. eCollection 2014.

20.

The landscape of metastatic progression patterns across major human cancers.

Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, Wolf T, Warth A, Dietel M, Anagnostopoulos I, Weichert W, Wittschieber D, Stenzinger A.

Oncotarget. 2015 Jan 1;6(1):570-83.

Supplemental Content

Loading ...
Support Center